Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial

(2014) P. Chevallier et al.   HAEMATOLOGICA

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients

(2014) L. S. Muffly et al.   HAEMATOLOGICA

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission

(2013) Ki-Seong Eom et al.   AMERICAN JOURNAL OF HEMATOLOGY

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

(2013) Brian Kornblit et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia

(2013) Yi-Bin Chen et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research

(2013) Mehdi Hamadani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies

(2013) Andrew M. Brunner et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease

(2013) Raynier Devillier et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients

(2013) A Bryant et al.   BONE MARROW TRANSPLANTATION

Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery

(2013) Frank Gärtner et al.   CYTOTHERAPY

The Evolving Role of Stem Cell Transplantation in Chronic Lymphocytic Leukemia

(2013) Peter Dreger   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

(2013) V Bachanova et al.   LEUKEMIA

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

(2012) Mauricette Michallet et al.   ANNALS OF HEMATOLOGY

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

(2012) E. Warlick et al.   BLOOD

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

(2012) U. Bacher et al.   BLOOD

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results

(2012) I. F. Khouri et al.   BLOOD

Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT

(2012) Patrice Chevallier et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

(2012) Martin Bornhäuser et al.   LANCET ONCOLOGY

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

(2012) F Baron et al.   LEUKEMIA

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome

(2012) J R Brown et al.   LEUKEMIA

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

(2011) Pervin Topcuoglu et al.   ANNALS OF HEMATOLOGY

Reduced-Intensity Allogeneic Transplantation Provides High Event-Free and Overall Survival in Patients with Advanced Indolent B Cell Malignancies: CALGB 109901

(2011) Thomas Shea et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life

(2011) Gheath Alatrash et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission

(2011) Sherif S. Farag et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation

(2011) Mark H. Kirschbaum et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

(2011) J. M. Pagel et al.   BLOOD

90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

(2011) A. K. Gopal et al.   BLOOD

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

(2011) R. J. Soiffer et al.   BLOOD

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

(2011) S M Luger et al.   BONE MARROW TRANSPLANTATION

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia

(2011) Issa F. Khouri et al.   CANCER

Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome

(2011) Stefanie Buchholz et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

(2011) R. Ram et al.   HAEMATOLOGICA

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2011) A. Sureda et al.   HAEMATOLOGICA

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

(2011) Mohamed L. Sorror et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Allogeneic Immunotherapy to Optimize the Graft-versus-Tumor Effect: Concepts and Controversies

(2011) D. L. Porter   Hematology-American Society of Hematology Education Program

Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation

(2010) Gordon Cook et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction

(2010) Jeffrey S. Miller et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

(2010) S. Cooley et al.   BLOOD

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

(2010) P. Dreger et al.   BLOOD

Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

(2010) M. Mohty et al.   BLOOD

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission

(2010) D. I. Marks et al.   BLOOD

TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions

(2010) C E Hill-Kayser et al.   BONE MARROW TRANSPLANTATION

Sequential Cytarabine and  -Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

(2010) T. L. Rosenblat et al.   CLINICAL CANCER RESEARCH

Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?

(2010) Brian L McClune et al.   CURRENT OPINION IN HEMATOLOGY

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials

(2010) J. L. Pinana et al.   HAEMATOLOGICA

Feasibility of Helical Tomotherapy for Debulking Irradiation Before Stem Cell Transplantation in Malignant Lymphoma

(2010) Cyrus Chargari et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

T-Cell–Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply Relapsed Follicular Lymphoma

(2010) Kirsty J. Thomson et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

(2010) Brian L. McClune et al.   JOURNAL OF CLINICAL ONCOLOGY

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia

(2010) Boglarka Gyurkocza et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

(2010) Haefaa Alchalby et al.   Current Hematologic Malignancy Reports

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes

(2009) Koen Van Besien et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reduced-Intensity Conditioning followed by Peripheral Blood Stem Cell Transplantation for Adult Patients with High-Risk Acute Lymphoblastic Leukemia

(2009) Anthony S. Stein et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Defining the Intensity of Conditioning Regimens: Working Definitions

(2009) Andrea Bacigalupo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research

(2009) Sergio Giralt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

(2009) Anne Sirvent et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

(2009) J. M. Pagel et al.   BLOOD

Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation

(2009) V. Bachanova et al.   BLOOD

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

(2009) J. Koreth et al.   BLOOD

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors

(2009) H. E. Kohrt et al.   BLOOD

Reduced intensity versus full myeloablative stem cell transplant for advanced CLL

(2009) E Peres et al.   BONE MARROW TRANSPLANTATION

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

(2009) John Koreth et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia

(2009) Olle Ringdén et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study

(2009) B-S Cho et al.   LEUKEMIA

Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase

(2009) Y Luo et al.   LEUKEMIA

Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning

(2008) Parameswaran Hari et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

(2008) I. F. Khouri et al.   BLOOD

Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience

(2008) Andrew R. Rezvani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Novel Preparative Regimens in Hematopoietic Stem Cell Transplantation

(2008) Lazaros Lekakis et al.   CURRENT PHARMACEUTICAL DESIGN

Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia

(2008) Lazaros Lekakis et al.   Expert Review of Anticancer Therapy

Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

(2008) M. Mohty et al.   HAEMATOLOGICA

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

(2008) P. Anderlini et al.   HAEMATOLOGICA

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

(2008) S. P. Robinson et al.   HAEMATOLOGICA

Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning

(2008) Mohamed L. Sorror et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma

(2008) Kirsty J. Thomson et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2007) Anna Sureda et al.   JOURNAL OF CLINICAL ONCOLOGY

Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival

(2007) David Valcárcel et al.   JOURNAL OF CLINICAL ONCOLOGY